UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1246-9
Program Prior Authorization/Notification
Medication Prevymis™ (letermovir)
P&T Approval Date 6/2018, 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 7/2023, 7/2024,
10/2024
Effective Date 1/1/2025
1. Background:
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for prophylaxis of
cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and
older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic
hematopoietic stem cell transplant (HSCT). Prevymis is also indicated for prophylaxis of CMV
disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who
are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV
seronegative [D+/R-]).1
2. Coverage Criteriaa:
A. Cytomegalovirus Prophylaxis
1. Initial Therapy
a. Prevymis will be approved based on one of the following criteria
(1) All of the following:
(a) Patient is a recipient of an allogeneic hematopoietic stem cell transplant
-AND-
(b) Patient is CMV-seropositive
-AND-
(c) Provider attests that Prevymis will be initiated between Day 0 and Day 28
post-transplantation (before or after engraftment) and is being prescribed as
prophylaxis and not treatment of CMV infection
-OR-
(2) All of the following:
(a) Patient is a recipient of a kidney transplant
© 2024 UnitedHealthcare Services Inc.
1
-AND-
(b) Patient is CMV-seronegative
-AND-
(c) Donor is CMV-seropositive
-AND-
(d) Provider attests that Prevymis will be initiated between Day 0 and Day 7
post-transplantation (before or after engraftment) and is being prescribed as
prophylaxis and not treatment of CMV infection
Authorization will be issued for 9 months.
2. Reauthorization
All requests for reauthorization will be denied by OptumRx. All requests for
continuation of therapy must be submitted through the appeals process to
UnitedHealthcare Pharmacy appeals for consideration.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Step Therapy, and/or Medical Necessity may be in place.
4. References:
1. Prevymis [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC.; August 2024.
Program Prior Authorization/Notification – Prevymis (letermovir)
Change Control
6/2018 New program
6/2019 Annual review with no change to coverage criteria. Updated reference.
6/2020 Annual review with no changes to coverage criteria.
6/2021 Annual review with no changes to coverage criteria.
6/2022 Annual review with no changes to coverage criteria. Updated
reference.
6/2023 Annual review with no changes to coverage criteria. Updated reference
and added state mandate footnote.
7/2023 Updated background with additional FDA approved indication and
© 2024 UnitedHealthcare Services Inc.
2
updated coverage criteria. Updated reference.
7/2024 Annual review with no changes to coverage criteria. Updated
reference.
10/2024 Updated background with expanded FDA approved indications in
pediatric population. No changes to coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services Inc.
3